Sector News

Sanofi invests €1 Billion to boost drug manufacturing in France

May 17, 2024
Life sciences

On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

In Vitry-sur-Seine, Sanofi wants to invest €1 billion to build a new facility that will double the site’s monoclonal antibody production capacity, where several biologics in development amongst Sanofi’s pipeline of drugs for the treatment of chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis or type 1 diabetes, could be produced.

At the Le Trait site in Normandy, Sanofi plans to invest €100 million to expand the capacity for biologics formulation, filling, device assembly and packaging, supporting the launch of future biologics and vaccines, as well as and the further growth of existing biologics production.

In Lyon Gerland, €10 million are to be invested to locate the production of TZield, a biologic for type 1 diabetes that Sanofi acquired in April 2023 and which has been manufactured outside Europe, in France.


comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach